Conference Handbook 2016
Translating UK scientific excellence into global therapeutic strategies
Pushing the boundaries of
Science MedImmune is the global biologics research and development arm of AstraZeneca, a global, innovationdriven biopharmaceutical business that focuses on the discovery, development and commercialisation of small molecule and biologic prescription medicines. MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic areas, including oncology; respiratory, inflammation and autoimmunity; cardiovascular and metabolic disease; infection and vaccines. For more information visit
www.medimmune.com
sponsors 33 ON Helix 2016 Sponsors Platinum Sponsors
contents
Gold Sponsor
Welcome
4
Advisory Board
6
Silver Sponsors
Keynote Speakers Speaker Profiles
Bronze Sponsor
Event Supporters
12
Floor Plan
13
Exhibitor Profiles
Corporate Patron
Corporate Sponsors
Media Supporters Wi-Fi codes available from Help Desk Keep up with the conversation #onhelix16
Partnering powered by
10-11 &14
Programme
Dates for your Diary 2016
Media Partners
7-8
17-20 22
4 welcome
welcome Dear ON Helix Participant, Harriet Fear CEO, One Nucleus
Welcome to our Translational Research Conference: ON Helix. One of the key issues described by many researchers is how to overcome the innovation gaps on the translational research pathway. This includes identifying barriers on which to concentrate, finding funding and meeting the right networks. These topics are of course covered by many conferences, but with ON Helix, One Nucleus brings together all these elements in one event under one roof for one day. Excellence in translational research is a core skill of many One Nucleus members and it seemed entirely appropriate that we should showcase that excellence to the UK and wider community; especially if it will stimulate and inspire young and emerging companies to follow in the footsteps of the people you will hear and learn from today. ON Helix aims to inform delegates how to turn early stage inventions and ideas into innovative health treatments. We will present the UK landscape of the business environment, funding, scientific and clinical research excellence. It will be a unique knowledge-sharing environment between academia and business. We are over the moon that we have some of the worlds’ best in our Keynote Speaker line-up – never before seen together on the same day!
ON Helix was launched in July 2013 to great acclaim with Sir William Castell, the then Chair of the Wellcome Trust who opened it, describing it as ‘a great day with a fantastic line-up (and) a great showcase for the strength of biomedical innovation’. Sir Mike Rawlins followed up by declaring it ‘THE translational event in the UK – it’s terrific’. So we decided to make it an annual fixture. You can expect stimulating keynote speeches, exceptional world class case study examples of collaborations and technologies and plenty of networking. The One Nucleus team and I know you will make full use of the presentations, debate, networking and the exhibitions to catch up with old friends and make some new ones, update yourselves on trends in the sector and create and scope out new business opportunities. I would like to take this opportunity to thank our fantastic ON Helix Advisory Board for all their support, all our sponsors and speakers for making it possible and of course you, our delegates, for bringing the event to life. I wish everyone an excellent event.
5
Partnering for scientific leadership At AstraZeneca, we believe in the power of what science can do to transform serious diseases like cancer, heart disease, diabetes, COPD and asthma. We also know that breakthrough science doesn’t happen in isolation. It happens through partnership.
Our expertise spans the entire life-cycle of a medicine and we have a rare combination of discovery and development strengths in small molecules and biologics, immunotherapies, protein engineering technologies and devices. These are reinforced by a strong focus on translational science and personalised healthcare.
To find out more, visit astrazeneca.com/Partnering
What science can do Circulating tumour DNA AstraZeneca has pioneered the use of circulating tumour DNA (ctDNA) in the diagnosis of cancer. Pieces of DNA break off from a tumour and circulate in the bloodstream where they can be analysed to give genetic information about a patient’s tumour. This allows healthcare professionals to determine the right treatment for the patient using a non-invasive blood test.
Atlas approval ID: 826,131.011 Expires 05 July 2016
6 advisory board
Thank You One Nucleus would like to take this opportunity to thank our ON Helix Advisory Board sincerely for all their support with the creation of today’s programme. It is very important to us that our events and activities are not shaped purely by the One Nucleus team, but that we seek, and receive, the highest quality expertise and input from distinguished people in the life science and healthcare sector. This Advisory Board’s collective credibility and experience is second to none. We are mindful that their time is precious and that calls on that time are many and varied. Which is what makes their commitment to ON Helix all the more special. Each and every Advisory Board member has taken a clear and personal interest in the development of the programme for you today and they should all be proud of their collective achievement. Not only have they been the all-important ‘critical friends’ to us, they have worked hard on the session themes and been incredibly generous in opening their contact books to signpost us to the very best speakers. It has been a pleasure working with them. We hope you enjoy the fruits of their and our labours.
Jane Dancer CEO, F-star
Hakan Goker Investment Director, MS Ventures
Flic Gabbay
Alan Palmer
Partner, TranScrip Partners
CSO, MS Therapeutics One Nucleus Board Member
Rob Pinnock
David Tapolczay
Independent
CEO, Medical Research Council Technology (MRCT)
keynote speakerss7
Dr Susan Windham-Bannister President and CEO, Biomedical Growth Strategies and Managing Partner, Biomedical Innovation Advisors Dr Susan Windham-Bannister is an internationally recognised innovation expert. She was named by the Boston Globe as one of the “10 Most Influential Women in Biotech” (2013) and by Boston Magazine as one of the “50 Most Powerful Women in Boston” (2011). Dr. Windham-Bannister currently serves as Managing Partner of Biomedical Innovation Advisors LLC, which she founded with Dr. Harvey Lodish, co-founder of Genzyme and a founding member of the Whitehead Institute, MIT. She also serves as the President and CEO of Biomedical Growth Strategies, LLC. Both of these advisory firms leverage Dr Windham-Bannister’s experience as the immediate past President and CEO of the Massachusetts Life Sciences Center (MLSC), a state-funded investment organisation charged with administering the $1-billion Life Sciences fund proposed by Governor Deval Patrick in 2007 and signed into law in June 2008. The MLSC is the hub for all sectors of the Commonwealth’s life sciences community – biotechnology, pharmaceuticals, medical devices, medical diagnostics and bioinformatics.
Professor David Roblin
Chief Operating Officer and Director of Scientific Translation, The Francis Crick Institute Professor David Roblin joined the Crick in February 2014 as COO and Director of Scientific Translation. He is a Fellow of the Royal College of Physicians and the Faculty of Pharmaceutical Medicine; honorary Professor of Medicine at Swansea University and Translational Medicine at St George’s. He serves as a member of a number of Committees including the Biomedical Catalyst Fund (Major Awards), MRC Confidence in Concept and the LEO Foundation; and Non-Executive Director to a number of biotech companies. He received his first degree in biochemistry from UCL and later qualified in medicine from St George’s Hospital. After practising medicine for five years, he entered the pharmaceutical industry where he held a number of significant leadership roles including Senior Vice President, Head of R&D for Pfizer’s European sites. His units were responsible for the R&D of several medicines including, azithromycin, ciprofloxacin, moxifloxacin, sildenafil (for pulmonary vascular disease), mariviroc, darifenacin and growth hormone including injectable devices. He was a co-founder and board member of the Innovative Medicines Initiative a 2 billion Euro public private partnership in precompetitive science. Particular areas of focus: The identification of science for translation and its acceleration to health and wealth benefits. Engaging scientists in collaboration in order to develop models of precompetitive open science in order to prove medical and biological hypotheses.
Professor Nick Lemoine
Medical Director, NIHR and Director, Barts Cancer Institute Professor Nick Lemoine’ s primary role is to direct the Theme Leads and Specialty National Leads in the development of strategic and implementation plans to support the delivery of high quality research studies by a well trained workforce. Nick is Director of the Barts Cancer Institute in London which has recently been ranked as one of the world’s top ten University departments of cancer research. He is also presently Director of Research & Development for Cancer & Surgery at Barts Health NHS Trust, the largest NHS Trust in the country. Nick was elected as a Fellow of the Academy of Medical Sciences in 2006.
8 keynote speakers Professor Sir John Savill
Chief Executive, Medical Research Council Professor Sir John Savill BA, MBChB, PhD, FRCP, FRCPE, FASN, FMedSci, FRS, FRSE, a clinician scientist from Edinburgh, took up the position as chief executive and deputy chair on 1 October 2010. The appointment was initially for three years; after which it was extended until April 2016, and subsequently to 30 September 2018. He was a member of the Council from 2002 to 2008 and chaired two Research Boards during this period. Between 2008 and 2010 John worked part-time as the chief scientist for the Scottish Government Health Directorates. He was knighted in the 2008 New Year Honours List for services to clinical science. John started his research career with a degree in Physiological Sciences from Oxford University in 1978, followed by degrees in Medicine at the University of Sheffield in 1981. He received a PhD from the University of London in 1989. After junior hospital appointments in Sheffield, Nottingham and London, he spent seven years in the Department of Medicine at Hammersmith Hospital with spells as an MRC clinical training fellow and Wellcome Trust senior clinical research fellow. In 1993, he moved to the chair of medicine, at the University of Nottingham, then in 1998 became professor of medicine at the University of Edinburgh, where he was the first director of the University of Edinburgh/MRC Centre for Inflammation Research, directing a group interested in the molecular cell biology of renal inflammation. In 2002, John was appointed as the first vice-principal and head of the College of Medicine and Veterinary Medicine, University of Edinburgh. He retains an ongoing, research active involvement with the University of Edinburgh part time throughout his appointment as our chief executive.
Dr Jane Osbourn Site Leader and VP Research and Development, MedImmune Jane Osbourn PhD joined MedImmune (formerly Cambridge Antibody Technology (CAT) and now the global biologics research and development arm of AstraZeneca) in 1993. An expert in antibody engineering, she originated several key publications and patents, and also made a significant contribution to the discovery and development of marketed drugs (Humira and Benlysta) and more than 40 clinical candidates. Prior to joining CAT, Jane obtained a First Class degree in Natural Sciences (Biochemistry) from the University of Cambridge and completed a PhD at the John Innes Centre for Plant Science Research in Norwich. This was followed by a Post-Doctoral position at Rutgers University, New Jersey before moving into medical research through a British Heart Foundation Post-Doctoral Fellowship at the Department of Medicine at Addenbrooke’s Hospital in Cambridge. Jane is Chair of the Board of Directors of the BioIndustry Association, a Director of Babraham Bioscience Technologies and a Director of Cambridge Enterprise. In addition, she has presented at a number of parliamentary Select Committees and has previously served as a Member of the UK Medical Research Council Industry Grant Award Assessment Panel.
Where Life Meets Science
Chesterford Research Park offers state of the art laboratory and office space alongside superb central facilities a community perfectly positioned for today’s thriving pharmaceutical and biotech companies. WWW.CHESTERFORDRESEARCHPARK.COM
01223 358114 dodson-jones.co.uk
DODSON JONES C HA R T ER ED S U R V EY OR S
savills.co.uk
01223 347 000
10 speaker profiles Davidson Ateh CEO, BioMoti
Davidson Ateh is a health entrepreneur. He is a past recipient of the prestigious Royal Society of Edinburgh/BBSRC Enterprise Fellowship and has a successful track record of financing disruptive ideas and progressing new technology. He is the CEO of BioMoti that is seeking to transform the treatment of cancer using its precision immunotherapeutic nanomedine platform: Oncojans™. BioMoti candidates have the potential to be groundbreaking cancer therapies for patients in need.
Georg Buchner
European Licensing Director, Amgen Georg Buchner, Ph.D. MBA is Amgen’s European Licensing Director. In his Role, Georg has responsibility for Amgen’s business development across therapeutic areas and technologies in UK, Benelux, Nordic regions, Italy and Israel. Georg previously worked as a consultant for various biotechnology companies in Europe, having worked and closed various deals in EU-based biotechnology companies including PolyTherics Ltd., Silence Therapeutics PLC, Novacta Biosystems Ltd., and Haptogen Ltd., where he lead the sale of the company to Wyeth . Georg has a Ph.D. in molecular genetics from King’s College London, U.K. and an MBA from the Judge Institute, University of Cambridge, U.K.
Rowan Gardner
CEO, Ozone Purification Rowan is CEO of Ozone Purification Ltd, a company creating significant new value for the food industry through efficiency, quality and increasing food safety. She has founded three companies (Synomics, Biolauncher and RowAnalytics) and participated in the commercialisation of 30 university technologies through creation of spin outs. Her experience spans start up, scale up and exit including IPO in the life science and data analytics sectors. Rowan also works with organisations seeking to understand capital flows in the start-up ecosystem. She is a biochemistry graduate of Oxford University.
Jackie Hunter
CEO, Stratified Medical Jackie Hunter is the Chief Executive Officer of Stratified Medical. Stratified Medical unites traditional pharmaceutical development methodology with Artificial Intelligence to augment the research capabilities of its drug scientists so that they can gain new insights to increase the efficiency of medicines development. Jackie has over thirty years of experience in the bioscience research sector, working across academia and industry including leading neurology and gastrointestinal drug discovery and early clinical development for GlaxoSmithKline. She founded OI Pharma Partners in 2010 to support the life science sector in harnessing the power of open innovation and most recently was Chief Executive of the Biotechnology and Biological Sciences Research Council. She holds a personal chair from St George’s Hospital Medical School, which was awarded in recognition of her contribution to bioscience research. In 2010 she was awarded a CBE in the Queen’s Birthday Honours list for Services to the Pharmaceutical Industry.
Iqbal Hussain
Senior Counsel, Johnson & Johnson Innovation Centre, London Iqbal is Senior Counsel at Johnson & Johnson Innovation Center, London where he is engaged in a full range of strategic and commercial transactions across the Consumer, Medical Devices and Pharma businesses of Johnson & Johnson. Iqbal joined Johnson & Johnson Innovation in February 2014. Iqbal has a strong corporate law background, having previously worked as an Associate at Ropes & Gray in London and Slaughter and May. Iqbal holds an LLB from the University of Sheffield and a postgraduate diploma from the Oxford Institute of Legal Practice. He is qualified as a solicitor in England and Wales.
speaker profiles 11 Piers Mahon
Director, Cancer Commons Dr. Mahon has a portfolio career as Director of Global Alliances for Cancer Commons, a Silicon Valley charity focused on developing stratified registries and novel research methods for less common cancer and as an advisor to pharma in using big data for more efficient precision medicine development. Previously he worked with Bain & Company in Boston, Paris and London in drug development, for instance as interim commercial leader at ARIAD pharma in Boston where he helped raise $500M for ponatinib’s launch.
Jon Moore
CSO Horizon Discovery Jon joined Horizon in October 2012 to lead its oncology target validation and drug discovery collaborations and became CSO in February 2014. Prior to this, he enjoyed 10 years at Vernalis culminating in a role as Head of Biology, where he was responsible for both cell biology and assay development activities. He also led the biology side of several innovative drug discovery programs and managed a major research alliance with GSK. His current research interests concern the identification of synthetic lethal targets to exploit signaling defects in cancer. Prior to making the move to industry, he gained extensive postdoctoral experience in the cell cycle control field working with first Sally Kornbluth at Duke and then Nobel Prize winner, Tim Hunt, at Cancer Research UK’s Clare Hall labs. He holds a PhD from the University of Newcastle upon Tyne and is a Fellow of the Society of Biology.
Sir Keith Peters
Senior Consultant, GSK From 1977 to 1987 Keith Peters was Professor and Director of the Department of Medicine at the Royal Postgraduate Medical School at Hammersmith Hospital and from 1987-2005 Regius Professor of Physic and the Head of the Clinical School at the University of Cambridge. His research has been on elucidation of immunological mechanisms underlying diseases of kidney and blood vessels, and this has led to new treatments – in particular the introduction of plasma exchange and immunosuppression - for these diseases. Cambridge, under his leadership, has become a major centre for clinical research, complementing the University’s longstanding strengths in basic biomedical science. He was a founder Fellow of the Academy of Medical Sciences and its second President. From 2006-2008 he was Interim Director of the MRC’s National Institute for Medical Research and initiated discussions which led to the establishment of the UK Centre for Medical Research and Innovation , the Francis Crick Institute . The Institute – which is now being built at St Pancras - is a partnership between the MRC, CRUK, The Wellcome Trust, and UCL, KCL and Imperial College. He has been involved in Singapore medicine in various ways, including advisory roles on Biopolis, the A Star Graduate Academy and the NUS-Duke Graduate Medical School. For the past 10 years he has been a Senior Consultant in R&D at GSK. He was Knighted in 1993 and elected Fellow of the Royal Society in 1995.
Keith Powell
Chairman, Domainex Keith has been in Biotechnology since it started. Having worked for GSK and ICI/Zeneca in genetics/molecular biology he led several large groups including Discovery, finally running the patent group. He then left for the USA and worked in a company on the West Coast, Maxygen, leading the small molecule group through the IPO and growing a business which eventually spun out as “Codexis”. On coming back to the UK, Keith worked with a fund called BBSF and acted as CEO for several of the companies in the portfolio, including Spear, sold to Advent International. He led Domainex through a merger with NCE to form a successful business in protein structure-based chemistry. Polytherics was built through organic growth since 2005 to a company of >30 people and is now part of Abzena. Keith is currently chairman of Domainex, Biomoti and Canbex and has a portfolio of other interests.
Emma Sceats
CEO, CN Bio Innovations CN Bio’s aim is to transform drug discovery and development by replacing animal testing with experiments on sophisticated mimics of human organs. Under Emma’s leadership CN Bio has completed deals with 25 pharma, raised £5 million in equity investment and secured £2 million research funding. CN Bio are currently working with the Massachusetts Institute of Technology on a $26 million US Government contract to build a human body-on-a-chip: a tablet sized device containing ten miniature interacting human organs. Emma is a chemist by training and was a Presidential scholar at MIT and a graduate scholar at Oxford.
12 programme 08.00
Registration
09.00
Welcome from One Nucleus
09.10
Keynote Addresses
09.10
09.40
Harriet Fear CEO, One Nucleus
Protagonist vs. Antagonist The Massachusetts Life Sciences Initiative: A New Role for Government in Accelerating Life Sciences Innovation
Susan Windham-Bannister President and CEO, Biomedical Growth Strategies and Managing Partner, Biomedical Innovation Advisors
Harvesting the Fruits of our Curiosity
David Roblin Chief Operating Officer and Director of Scientific Translation, The Francis Crick Institute
10.10
Coffee Break and Exhibition
11.00
Session 1: The Future of Medicines: Do Patients Make the Best Models? Chair Sir Keith Peters GSK
Panellists Jon Moore Horizon Discovery
12.00
Lunch, Ice Cream and Exhibition
13.00
Cambridge Science Centre Lunchtime Show
13.30
14.00
Rick Livesey The Gurdon Institute, University of Cambridge
Harnessing the Power of the NHS for Clinical Research: How the NIHR Clinical Research Network can Translate Discovery into Implementation in Health Care
Dominic J Wells Royal Veterinary College
Emma Sceats CN Bio Innovations
Nick Lemoine Medical Director, NIHR and Director, Barts Cancer Institute
Session 2: Licensing Your Ideas: The Role of Technology Transfer Offices Chair
Panellists
Jackie Hunter Stratified Medical
Iain Thomas Cambridge Enterprise
Sue Sundstrom University of Bristol
Georg Buchner Amgen
Iqbal Hussain Johnson & Johnson Innovation Center, London
15.00
Coffee Break and Exhibition
15.45
Session 3: ‘I Don’t Know What all the Fuss is About – Funding for Translational Research is Fantastic in the UK and we Don’t Really Need More’ Agree Or Disagree Chair Davidson Ateh BioMoti
Agree Piers Mahon Cancer Commons
Ian Tomlinson Apollo Therapeutics Investment Committee
Disagree Keith Powell Domainex
Rowan Gardner Ozone Purification
16.45
The MRC Promotes Partnership Between UK Academia and Industry
Sir John Savill Chief Executive, Medical Research Council
17.15
Closing Address
Jane Osbourn Site Leader and VP Research and Development, MedImmune
17.30
Drinks Reception
18.30
Close
floor plan 13
11
10
9
8
7
6
5
4
3
2
Ice Cream Van
1
14
13
12
16
15
Entrance to ON Helix Press Area
17
i
18
R
20
19
Auditorium
AM STE
:E
Se
at in
e ctiv olle DC
g
Key
r Pa Public engagment space
ge re brid t Cam nce Cen e Sci
er
tn
ing Cambridge Science Centre Show
i
Help desk
R
Registration desk Refreshments Toilets Fire Exits
Exhibitors 1 MedImmune 2 AstraZeneca 3 Horizon Discovery 4 Medical Research Council Technology 5 Wellcome Genome Campus 6 Innovation Forum 7 Propath 8 S-Tech 9 Chesterford Research Park 10 United Airlines 11 Queen Mary University of London 12 Norwich Research Park
13 Experimental Cancer Medicine Centres (ECMC) Network 14 First Sight Media 15 Hammersmith Medicines Research 16 Illingworth Research 17 InterFocus 18 Sigma-Aldrich 19 British Pharmacological Society 20 United Life Sciences Press Area BioStrata
14 speaker profiles Sue Sundstrom
Head of Research Commercialisation, University of Bristol Sue spent 20 years with AstraZeneca where she held international commercial positions including General Management, marketing and global business development. She was responsible for multi-million dollar deals, the sale of non-strategic companies and the creation of new companies as strategic priorities evolved. On leaving AstraZeneca she joined the University of Southampton, as Head of Lifesciences where her team handled contracts, licensing and spinout creation. Moving to the University of Bristol, in 2009 she became Head of Commercialisation and Impact Development in 2012, working across the university to generate commercial, societal and policy impacts.
Iain Thomas Head of Life Sciences, Cambridge Enterprise Cambridge Enterprise’s Life Sciences product portfolio includes alemtuzumab (Sanofi), breast cancer markers (Brevagen) and mouse touch screen chambers (Campden Instruments). Recent spin-outs include Morphogenix, Mission Therapeutics, Cambridge Epigenetix, XO1 Therapeutics, Z-factor and Phoremost. Recent transactions include licences in fields as diverse as therapeutics, diagnostics, biofuels, IVF and epigenetics and the sale of XO1 to Johnson & Johnson. Iain led discussions with GSK in respect of the University of Cambridge–GSK open innovation drug discovery initiative based at the SBC and was the CE lead for the Apollo Therapeutics Fund.
Ian Tomlinson Chairman, Apollo Therapeutics Investment Committee Ian Tomlinson has over 25 years of experience in the lifesciences sector from academic research to biotech startup to big pharma. He founded Domantis Limited with Sir Gregory Winter, which was acquired by GSK for $454 million. He then served as Senior VP, Head of Worldwide Business Development and Head of Biopharm R&D at GSK. Following he departure from GSK earlier this year, he is now Chairman of the Board at the Stevenage Bioscience Catalyst, UK’s first open innovation biomedical campus. He is also Chairman of the Investment Committee for Apollo Therapeutics, a £40 million fund dedicated to turning academic biotechnologies into novel medicines in collaboration with Astrazeneca, GSK, J&J, Imperial College, UCL and the University of Cambridge. Dr Tomlinson graduated from Trinity College, Cambridge, UK. He then spent 11 years at the MRC Laboratory of Molecular Biology, where he worked on antibody genes, antibody structure and various antibody technologies prior to starting his career in industry.
Dominic Wells Professor in Translational Medicine, Royal Veterinary College Dominic (Nic) Wells qualified from Cambridge University as a veterinary surgeon in 1984. After several years in very mixed general practice he studied comparative exercise physiology writing his PhD on hummingbird flight energetics at the University of Wyoming (USA). In 1990 he took a temporary lectureship at the Royal Veterinary College in London and a full lectureship in 1992. In 1995 he moved to the Charing Cross and Westminster Medical School, now part of the Faculty of Medicine at Imperial College London and was appointed Professor in 2005. In 2010 he moved back to the RVC as Professor in Translational Medicine. He works predominantly on testing potential therapies for neuromuscular diseases.
15
13 July 2017 Cambridge, UK
Translating UK scientific excellence into global therapeutic strategies
onhelix.com | #onhelix17
Wellcome Genome Campus Conference Centre, Cambridge
genesis 2016
London’s premier Life Science & Healthcare networking conference QEII Centre, Westminster, London | 1 December 2016 Genesis 2016, brought to by One Nucleus will focus on Biomedical Innovation: The Science, Technology and Business of the 21st Century and will build on our previous 15 years of experience in assembling a forum where industry executives, investors, academic researchers, policy makers and expert advisers can exchange ideas. Genesis 2016 will feature: •
Plenary Presentations and Panel Debates
•
Parallel Leadership Streams covering Case Study Deals, Therapeutic Advances, Digital Health and Nurturing Innovation
•
700+ delegates from across the international Life Science and Healthcare industry
•
50+ international exhibitors
•
Prescheduled face to face meetings
•
Genesis Fringe: focused events pre and post Genesis
•
2016 BioNewsRound Award Workshops
Join in the conversation #ongc16 genesisconference.com
exhibitor profiles 17
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, in three main therapy areas - respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology – as well as in infection and neuroscience. We believe the best way we can help patients is to focus on breakthrough science in order to uncover disease mechanisms and develop novel, targeted therapies that interact with them. This is at the heart of our purpose as a company: to push the boundaries of science to deliver life-changing medicines. AstraZeneca’s science exploits our rare combination of capabilities in small molecules and biologics, immunotherapies, protein engineering technologies and devices. We build on our own capabilities by collaborating with world-renowned scientists and academic institutions and partner with like-minded science-led companies.
BioStrata Marketing as a specialist marketing agency working in life science, our team is fluent in the languages of science and business. We combine PhD level knowledge with decades of marketing experience to develop integrated programmes that deliver results for life science companies. Everything we do starts with the development of a strategy that will help our clients succeed. As a truly integrated agency, we can then provide all of the tactical services required to help them realise their goals, from creative design and digital marketing through to content development, technical writing, social media and traditional PR tactics. We are also a leading specialist in the strategic use of cutting-edge methodologies such as inbound and content marketing. Tel: 01223 828 200 Email: crussell@biostratamarketing.com Website: www.biostratamarketing.com Contact: Clare Russell
The British Pharmacological Society is a charity with a mission to promote and advance the whole spectrum of pharmacology. We are a friendly and collaborative global community, with over 3,500 members from more than 60 countries worldwide. We welcome membership applications at www.bps.ac.uk/membership. The Society covers pharmacology in all its forms, including laboratory, clinical, and toxicological aspects. Our members work in academia, industry, regulatory agencies and the health services, and many are medically qualified. Founded in 1931, the Society leads the way in the research and application of pharmacology around the world through our scientific meetings, peer-review journals and educational initiatives. Stand 19
Press Area
Stand 2
Cambridge Science Centre is a venue for exhibitions, shows, workshops and talks: a place in which to discover, to create and to learn. It acts as a gateway into some of the amazing scientific research in this great city and from around the world. Every year we host the annual engineering extravaganza, Chain Reaction. At this spectacular event , families, schools and local companies will get stuck into building a huge chain of crazy contraptions that launch one another around the room and across the stage. We are a registered educational charity providing a permanent interactive public science centre for Cambridge, UK. Interactive exhibits throughout the day Show 13.00 - Behind the Partnering area
Chesterford Research Park is home to leading bioscience innovators including Axol Biosciences, BioFocus, Diagnostics for the Real World and Isogenica. Part of the South Cambridge life sciences cluster, Chesterford’s prestigious environment and range of facilities provides flexible and future proofed modern and energy efficient laboratory and office space for both established and early stage biotechnology and pharmaceutical R&D companies. Close to the A11 and M11 this tranquil, low density development is perfectly positioned within 20 minutes of Cambridge. London is reachable in under an hour by train and Stansted airport is just 20 minutes’ drive away. Katherine Maguire, Park Manager Katherine.maguire@eu.jll.com Tel: +44 (0)1799 532252 www.chesterfordresearchpark.com Stand 9
The ECMC Initiative is a network of the top UK sites on experimental cancer medicine that collaboratively deliver early phase clinical trials and associated translational activity to high standards. Funded in partnership by Cancer Research UK and the four Health Departments of the UK nations, it has received an investment of £70 million since its conception in 2007. With 18 Adult and 9 Paediatric centres distributed throughout the UK, the Initiative brings together world-class pockets of expertise covering all cancers and treatment modalities. Both Networks provide industry partners with the opportunity to collaborate with academic world-leaders and obtain access to cutting-edge, early-stage innovation, and integration with clinical Centres. In 2014/15 alone, 48 companies set up new partnerships with ECMCs which resulted in over £73,000,000 of leveraged funds. Stand 13
18 exhibitor profiles
First Sight Media is a professional video production and streaming specialist, which has been delivering creative live events, training and promotional videos for over 20 years. Specialising in live and on-demand video streaming, communicating your message through us, over the internet has never been easier. We also offer the ability for you to enhance your conferences and webinars through our bespoke presentation software iPresenter, allowing you to deliver high definition video of your speaker simultaneously with their presentation slides online.
Hammersmith Medicines Research (HMR ) is a CRO specialising in phase 1 and early phase 2 studies. We’ve done more than 730 trials – almost all conceivable types, many of them first administration to humans. We have: new premises with 145 beds; 240 staff; MHRA GCP and GMP approval; laboratory and pharmacy accreditation; and ISO9001 quality system. Trio Medicines is a subsidiary company of HMR, with a portfolio of 3 compounds at different stages of development. Stand 15
Whatever your audience, we can offer a tailored solution to effectively communicate your message through creative multimedia. Visit our website to see examples and get in touch. W: www.firstsightmedia.co.uk Tel No 0800 072 8753 Stand 14
Horizon Discovery is a world-leading gene editing company that designs and engineers genetically-modified cells and then applies them in research and clinical applications that advance human health. Horizon’s core capabilities are built around its proprietary translational genomics platform, a highly precise and flexible suite of gene editing tools (rAAV, ZFN and CRISPR) able to alter almost any gene sequence in human or mammalian cell-lines. Horizon offers over 23,000 catalogue products and related research services, almost all of which are based on the generation and application of cell and animal models that accurately recapitulate the disease-causing genetic anomalies found in diseases like cancer. Horizon’s commercial offering has been adopted by c1,400 unique research organisations in over 50 countries as well as in the Company’s own R&D pipeline to support: a greater understanding of the genetic drivers of disease and the development of molecular, cell and gene therapies that can be prescribed on a personalised basis. Stand 3
Illingworth Research is a full service clinical CRO with experience across all phases of development from Phase I / proof of concept studies to post-marketing studies for small molecules, biotechnology products, medical devices and diagnostics. With a network of clinical infrastructure covering most therapeutic areas varying from clinical research units, primary, secondary and tertiary care sites across Europe and with partners in North America and Australasia, Illingworth has the capability to deliver large multi-centre global studies. Illingworth provides research nurses for patient homecare to support studies for optimisation of patient retention and compliance. Illingworth also offers a medical photography service. Stand 16
The Innovation Forum is a global network of over 10,000 innovative companies, academics, industry professionals, investors and policy makers. Led by our flagship Innovation Forum Leaders Conference now organised for the 3rd time in Cambridge on the 21st and 22nd September 2016, we deliver over 40 events annually in 13 global cities on three continents. We also run a global IMAGINE IF! accelerator for early stage pre-seed level healthcare and clean tech ventures. To learn more about our work please visit: www.inno-forum.org Stand 6
InterFocus is one of the UK’s leading laboratory furniture manufacturers and installers based just outside Cambridge, we have an impressive list of clients that includes both Cambridge and Oxford Universities, the Medical Research Council, Kings College Hospital London, Welsh Water, Unilever and GlaxoSmithKline. We have over 30 years’ experience in providing both laboratory design, manufacture and installation solutions alongside providing complete turnkey laboratory solutions for our clients. Our modern manufacturing facility allows us to provide both standard and bespoke solutions and provide quick turnaround times. And using the latest CAD technologies we are able to work and collaborate on BIM projects and also provide detailed 3D visualisations of the proposed laboratory designs for our clients. We have also recently opened a new showroom facility showcasing our laboratory product range. For more information visit our website at www.mynewlab.com, call us on 01223 894833 or email sales@interfocus.co.uk. Stand 17
exhibitor profiles 19
Medical Research Council Technology (MRCT) is an independent life science medical research charity committed to improving positive patient outcomes everywhere. As a champion for human health, MRCT partners with academic, biotechnology, pharmaceutical and charity organisations to move promising medical research forward into viable and accessible patient treatments. As a self-funded charity, income is reinvested to support translating research from the bench to patient. MRCT offers commercialisation and IP management skills and diagnostic and drug discovery expertise, specialising in small molecules and therapeutic antibodies. MRCT projects have led to several approved drugs, changing the lives of countless patients by harnessing the potential of science. mrctechnology.org Stand 4
MedImmune is the global biologics research and development arm of AstraZeneca with candidate biologics and vaccines that currently compromise approximately 50 percent of AstraZeneca’s overall R&D pipeline. It has one of the most robust and promising pipelines in the biologics industry, with more than 120 biologics in research and development and over 40 projects in clinical stage development. MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic areas, including oncology; respiratory, inflammation and autoimmunity; cardiovascular and metabolic disease; and infection and vaccines. Approximately 2,500 full-time employees are in the US and UK. MedImmune is headquartered in Gaithersburg, MD – one of AstraZeneca’s three global R&D centres, along with Cambridge, UK and MoIndal, Sweden. Stand 1
Norwich Research Park is a vibrant community comprised of innovation led companies, 4 world leading science research institutes, the University of East Anglia and the Norfolk & Norwich Hospital. The key areas of focus are MedBiotech, Food & Health, Industrial Biotech and Agritech. The Park provides a supportive environment for innovation and growth. Services address the needs of science based businesses and include clinical trials facilities, biorepository, shared laboratories, extensive genomics, proteomics & metabolite services. There is a range of cost effective accommodation options comprising offices and laboratories with flexible terms plus development land for further growth. Less than 20 minutes’ drive from Norwich International Airport and only 1 hour from Cambridge, Norwich Research Park is currently home to over 40 businesses and 3,000 researchers and clinicians. Stand 12
Propath is a leader in molecular pathology and histopathology. As a GLP and GCP compliant facility we provide expert, regulatory-compliant services in tissue cross-reactivity, immunohistochemistry, in-situ hybridisation, histopathology, image analysis and whole-slide digital scanning. Our focus is on preclinical safety assessment and clinical trial support for pharmaceuticals, therapeutic antibodies, chemicals and medical devices; with strengths in supporting regulatory toxicology and clinical projects and assessing on/off‐target binding and bio-distribution of novel therapeutic antibodies. Propath’s reputation has been gained by focusing relentlessly on the quality of our advice, the standard of our work and the responsiveness of our service.
The Queen Mary University of London Life Sciences Initiative (LSI) is a multidisciplinary endeavour that aims to establish a unique life sciences cluster in London. We are working with partners from the local community, higher education, NHS and industry to make a significant contribution to the health of people at regional, national and international levels.
Sigma-Aldrich, a leading Life Science and High Technology company focused on enhancing human health and safety, manufactures and distributes more than 230,000 chemicals, biochemicals and other essential products to more than 1.4 million customers globally in research and applied labs as well as in industrial and commercial markets.
The LSI is addressing fundamental questions relating to post-genomic population health – using genetic information gained as a result of sequencing the human genome to understand the complex interaction between genes and the environment in order to improve the health of individuals, the local and the wider population.
With three distinct business units – Research, Applied and SAFC Commercial – Sigma Aldrich is committed to enabling science to improve the quality of life.f life.
Stand 7
Stand 11
Stand 18
20 exhibitor profiles
S-Tech has supported the biotech and life science related industries since 1982 by arranging insurance cover against a wide range of asset, liability and financial risks. We work with you to fully understand your business to achieve the widest possible insurance protection. We are a fully independent and Chartered Insurance Broker with access to insurance markets in the UK, Lloyds and overseas. Our clients range from start-up to international organisations both in the UK and abroad. We offer a wide range of services to One Nucleus members; please check the Support Supplier page or search for S-Tech on the One Nucleus website.
United offers comprehensive access to the U.S. from seven U.K. and two Irish airports, and onward connections to over 300 destinations across the Americas. With services from London Heathrow, Manchester, Birmingham, Newcastle, Edinburgh, Glasgow, Belfast, Double and Shannon, United offers nonstop transatlantic flights from more U.K. and Irish cities than any other airline. And you won’t just arrive at your destination: you’ll arrive refreshed, thanks to our high levels of inflight comfort and personal service. From adjustable seats in United Economy® to 180 degree flat-beds in United BusinessFirst®, air travel is a pleasure.
United Life Sciences (ULS) is a strategic partnership representing over 1,200 life science and healthcare organisations across the UK and internationally. The ULS collaboration has member and the wider UK life science sector benefit at the heart of its purpose and is the basis for all joint activities. It strives to avoid duplication of effort and coordinates the five organisations’ activities whilst recognising each other’s areas of strength so that member companies can benefit from more effective and coherent sector support.
Stand 8
Stand 10
BIA – Steve Bates, SBates@bioindustry.org
One Nucleus - Harriet Fear, harriet@onenucleus.com
Bionow - Geoff Davison, geoff.davison@bionow.co.uk BioPartner - Lin Bateson, lin@biopartner.co.uk MediWales - Debbie Laubach, debbie.laubach@mediwales.com Stand 20
One Nucleus
Directory 2016 The Wellcome Trust Sanger Institute is one of the world’s leading genome centres. Through its ability to conduct research at scale, it is able to engage in bold and long-term exploratory projects that are designed to influence and empower medical science globally. Institute research programmes are being used to develop new diagnostics and treatments for human disease. The Institute is based at the Wellcome Genome Campus, a world class hub for genomics and bioinformatics. July 2016 sees the opening of its Biodata Innovation Centre, enabling a growing number of commercial sector collaborators to join its shared vision of delivering life changing science. Stand 5
New Exhibition opens Tuesday 5th July
ON Helix Special Offer KIDS GO FREE from 5th July until 4th September ON PRODUCTION OF THIS PAGE One use only
Get hands-on and discover how all living things survive and thrive on Earth.
Cambridge Science Centre 18 Jesus Lane, Cambridge CB5 8BQ www.cambridgesciencecentre.org
Facilities Management One Nucleus provides project management for all your laboratory fit-outs. • • • •
Setting up of laboratory equipment service contracts Building maintenance contracts Insurance Purchasing
Contact: richard@onenucleus.com Tel: 01223 896453
• Cleaning contracts • Utilities • Budgeting
22 dates for your diary 2016 Key
One Nucleus Events United Life Sciences Member Events
OCT 19
M11 Health Enterprise Forum Harlow
JUL 06
BioWednesday LBIC, London
OCT 20
BIA - UK Bioscience Forum One Nucleus Member Discount London
JUL 06
MediWales- MediWales Connects One Nucleus Member Discount Cardiff
NOV 02
Network Meeting Stevenage Bioscience Catalyst
JUL 13
Network Meeting Summer Social The Nucleus, Little Chesterford
NOV 03
Bionow - BioInfect One Nucleus Member Discount Alderley Park
SEP 07
BioWednesday Gowling WLG, London
NOV 22-23
BIA - bioProcessUK One Nucleus Member Discount
SEP 22
Leadership Seminar Penningtons Manches, London
NOV 29
MediWales - UK Healthtech Conference One Nucleus Member Discount Cardiff
SEP 29
Bionow - BioCap One Nucleus Member Discount Alderley Park
NOV 30
Genesis Fringe Event: BioClusters Seminar: Collaboration, Competition and Funding Canada House, London
OCT 05
BioWednesday Queen Mary BioEnterprises, London
DEC 01
Genesis QEII Centre, London
OCT 12
Network Meeting Mills & Reeve LLP, Cambridge
DEC 14
Network Meeting Pub Social, Cambridge
Careers at Horizon Discovery We realised a long time ago that the best way to sustain our success is to give talented people the environment they need to excel. So that’s what we do. That means constant challenge, variety, freedom to map your own career path, respect and support. As a growing company we offer competitive salaries and an attractive flexible benefits package.
www.horizondiscovery.com
One Nucleus Limited Cambridge The Portway Granta Park Cambridge CB21 6GS United Kingdom +44 (0) 1223 896 450 info@onenucleus.com @OneNucleus onenucleus.com